asciminib
Bristol Myers Squibb Presents Encouraging Data from Phase 1 Breakfree-1 Study of CD19 NEX-T™ CAR T Cell Therapy in Three Chronic Autoimmune Diseases at ACR Convergence 2025
Pressure score
58
Momentum score
14
Why This Matters
Bristol Myers Squibb is an emerging emerging competitor with Phase I activity on asciminib in Hematology · Chronic Myeloid Leukemia; while behind Novartis (development-stage), accelerated readouts could compress Novartis's strategic window.
Competitive Assessment
- Threat type
- emerging competitor
- Development stage
- Phase I
- Stage gap
- Stage comparison unavailable — competitor development phase not fully evidenced.
- Market share risk
- Moderate share risk if competitor advances before the signal sponsor establishes label leadership.
Strategic Action
Align with signal posture: monitor. Monitor emerging competitor activity and refresh competitive intelligence after material readouts.
Overlap Analysis
Source Analysis
Bristol Myers Squibb Presents Encouraging Data from Phase 1 Breakfree-1 Study of CD19 NEX-T™ CAR T Cell Therapy in Three Chronic Autoimmune Diseases at ACR Convergence 2025
Bristol Myers Squibb document relevant to the signal.
Source: Bristol Myers Squibb
View source documentRelated Signal
Novartis initiates pediatric study for asciminib in Chronic Myeloid Leukemia
Open signalCompetitor Position
Competitor race
Pressure ranking for this signal's competitive set
Position: #2 of 3
Lilly
1 competitive finding
Top program: asciminib
- Pressure
- 75
- Momentum
- 51
- Threat
- regulatory competitor
- Stage
- Approved
75LillyHighasciminib·Approved
Bristol Myers Squibb
1 competitive finding
Top program: asciminib
- Pressure
- 58
- Momentum
- 14
- Threat
- emerging competitor
- Stage
- Phase I
58Bristol Myers SquibbMediumasciminib·Phase I
Roche
2 competitive findings
Top program: asciminib
- Pressure
- 55
- Momentum
- 51
- Threat
- direct competitor
- Stage
- Approved
55RocheMediumasciminib·Approved